MGNK — Mologen AG Share Price
Last trade - 00:00- €0.06m
- -€2.76m
- €3.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1879.21% | ||
| Return on Equity | n/a | ||
| Operating Margin | -15845.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.01 | 0.04 | 0.07 | 0.05 | 3.05 | 0.1 | 42.5 | 68.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mologen AG is a Germany-based company engaged in the biotechnology and medical research industry. The Company specializes in the research and development of drugs in the fields of oncology and infectious diseases. The Company develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.
Directors
- Oliver Krautscheid CSU (53)
- Stefan Manth CEO (65)
- Gerhard Greif SUB
- Michael Schultz SUB
- Friederike Zahm SUB
- Last Annual
- December 31st, 2018
- Last Interim
- September 30th, 2019
- Incorporated
- February 9th, 1998
- Public Since
- June 18th, 1998
- No. of Employees
- 43
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Hamburg Stock Exchange
- Shares in Issue
- 12,435,774
- Address
- Koenigin-Luise-Str. 27, BERLIN, 14195
- Web
- http://www.mologen.com/de/
- Phone
- +49 308417880
- Auditors
- Baker Tilly Roelfs AG Wirtschaftsprufungsgesellschaft
Similar to MGNK
Q2M Managementberatung AG
Hamburg Stock Exchange
FAQ
As of Today at 01:16 UTC, shares in Mologen AG are trading at €0.01. This share price information is delayed by 15 minutes.
Shares in Mologen AG last closed at €0.01 and the price had moved by -83.33% over the past 365 days. In terms of relative price strength the Mologen AG share price has underperformed the FTSE Global All Cap Index by -81.93% over the past year.
The overall consensus recommendation for Mologen AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Mologen AG does not currently pay a dividend.
Mologen AG does not currently pay a dividend.
Mologen AG does not currently pay a dividend.
To buy shares in Mologen AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.01, shares in Mologen AG had a market capitalisation of €0.06m.
Here are the trading details for Mologen AG:
- Country of listing: Germany
- Exchange: HAM
- Ticker Symbol: MGNK
Based on an overall assessment of its quality, value and momentum Mologen AG is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mologen AG is €25.20. That is 503900% above the last closing price of €0.01.
Analysts covering Mologen AG currently have a consensus Earnings Per Share (EPS) forecast of -€1.30 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mologen AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -57.89%.
As of the last closing price of €0.01, shares in Mologen AG were trading -44.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mologen AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mologen AG's management team is headed by:
- Oliver Krautscheid - CSU
- Stefan Manth - CEO
- Gerhard Greif - SUB
- Michael Schultz - SUB
- Friederike Zahm - SUB